Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches

International Journal of Infectious Diseases

Volumn 4, Issue 3, 2000, Pages 158-177

  Murray, Henry W ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Box 136 ^*  (United States)

Author keywords

Amphotericin B; India; Kala azar; Leishmania; Pentavalent antimony

Indexed keywords

ABANATE; AMINOGLYCOSIDE; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HYDROXYSTILBAMIDINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; STIBOGLUCONATE SODIUM;

CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INDIA; MONOTHERAPY; NONHUMAN; PROTOZOAL INFECTION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

EID: 0033658753     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(00)90078-X     Document Type: Review

References (205)

1. Recent advances in tropical medicine
2. Clinical spectrum of leishmaniasis
3. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
4. Treatment of Mediterranean visceral leishmaniasis
5. Leishmaniasis: Public health aspects and control
6. Leishmaniasis
7. Practical guide for the treatment of leishmaniasis
8. The identification of kala-azar and the discovery of Leishmania donovani
9. On the possibility of the occurrence of trypanosomiasis in India
10. On the possibility of the occurrence of trypanosomiasis in India
11. Epidemiology of visceral leishmaniasis in India
12. Kala-azar cases and deaths
13. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm
14. Indian kala-azar caused by Leishmania tropica
15. East African kala-azar with special reference to the pathology, prophylaxis, and treatment
16. Recent research on kala-azar in India
17. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis
18. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries
19. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)
20. Treatment of visceral leishmaniasis in children with liposomal amphotericin B
21. Endemic kala-azar in eastern Sudan: A longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis
22. New perspectives on a subclinical form of visceral leishmaniasis
23. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi
24. Evidence of subjects sensitized to Leishmania infantum on the French Mediterranean coast: Differences in gamma interferon production between this population and visceral leishmaniasis patients
25. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France
26. Studies in Mediterranean leishmaniasis. 3. The leishmanin skin test in kala-azar
27. Granulomatous inflammation: Host antimicrobial defense in the tissues in visceral leishmaniasis
28. An analysis of T cell responsiveness in Indian kala-azar
29. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi
30. Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis
31. Leishmanin skin test in clinical and subclinical kala-azar cases
32. Immunity in kala-azar
33. Successful response to chemotherapy in experimental visceral leishmaniasis: Requirement for T cells and effect of lymphokines
34. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis
35. Leishmania and human immunodeficiency virus coinfection: The first 10 years
36. Kala-azar as an AIDS-related opportunistic infection
37. Differential production of Th1- and Th2-derived cytokines does not determine the generally controlled or vaccine-induced rate of cure in murine visceral leishmaniasis
38. Interleukin 12 is required for natural killer cell activation and T helper 1 cell development in experimental leishmaniasis
39. The regulation of immunity to Leishmania major
40. Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis
41. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma
42. Interleukin-10 production correlates with pathology in human Leishmania donovani infection
43. Behavior of visceral Leishmania donovani in an experimentally-induced Th2 cell-associated response model
44. Transforming growth factor-β in leishmanial infection
45. The importance of TGF-β in murine visceral leishmaniasis
46. Depletion of IL-4 in BALB/c mice with established Leishmania major infection increases the efficacy of antimony and promotes Th1-like responses
47. Circulating Th1 cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis
48. Splenic cytokine responses in Indian kala-azar before and after treatment
49. Presence of circulating levels of interferon-γ, interleukin-10 and tumor necrosis factor-α in patients with visceral leishmaniasis
50. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis
51. Interleukin 12 is effective treatment for an established systemic intracellular infection: Experimental visceral leishmaniasis
52. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam
53. Immunochemotherapy for intracellular Leishmania donovani infection: Interferon-γ plus pentavalent antimony
54. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis
55. Cure of progressive murine leishmaniasis: Interleukin 4 dominance is abolished by transient CD4 T cell depletion and T helper cell type 1-selective cytokine therapy
56. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 area potent vaccine in a murine model of intracellular infection
57. Effect of treatment with interferon-γ alone in Indian visceral leishmaniasis
58. Treatment of visceral leishmaniasis with pentavalent antimony and interferon-gamma
59. The role of interferon-γ in the treatment of visceral and diffuse cutaneous leishmaniasis
60. Successful treatment of refractory visceral leishmaniasis in India using antimony plus IFN-γ
61. Immunochemotherapy for an intracellular infection: Accelerated response using IFN-γ in visceral leishmaniasis
62. Response to interferon-γ plus antimony in Indian visceral leishmaniasis
63. Short-term treatment of visceral leishmaniasis of the Old World with low dose interferon-gamma and pentavalent antimony
64. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis
65. Interleuken 12 regulates the response to chemotherapy in experimental visceral leishmaniasis
66. Chemotherapy of leishmanial diseases: A resume of recent researches
67. Treatment of Chinese kala-azar with sodium antimony gluconate
68. Comparison of two dose schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya
69. Control of the leishmaniases
70. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
71. Experimental treatment with sodium stibogluconate of hamsters infected with Leishmania (Leishmania) chagasi and Leishmania (Leishmania) amazonensis
72. Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis
73. Treatment of kala-azar with amphotericin B
74. The treatment of kala-azar, the new approaches to an old problem
75. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: A randomised study
76. Evaluation of diamidine compounds (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India
77. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonials
78. Comparison of regimes of treatment of antimony-resistant kala-azar patients: A randomized study
79. Amphotericin versus pentamidine in antimony-unresponsive kala-azar
80. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar
81. Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate
82. Allopurinol in the treatment of visceral leishmaniasis
83. Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India
84. The efficacy and safety of ketoconazole in visceral leishmaniasis
85. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar
86. Ketoconazole in visceral leishmaniasis
87. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol
88. Genetic control of drug-induced recovery from murine visceral leishmaniasis
89. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis
90. Effect of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis
91. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani
92. Hexadecylphosphocholine: Oral treatment of visceral leishmaniasis in mice
93. The activities of four anti-cancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei
94. Short- and long-term efficacy of hexadecylphosphocholine in established Leishmania infantum infection in BALB/c mice
95. Recent advances in the treatment of visceral leishmaniasis
96. Therapeutic effect of interferon-gamma gene transfer in experimental visceral leishmaniasis
97. Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania
98. Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani
99. Treatment of cutaneous leishmaniasis with nitric-oxide donor
100. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-γ-dependent mechanisms
101. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paraomomycin in a murine model of visceral leishmaniasis
102. Role and effect of interleukin-2 in experimental visceral leishmaniasis
103. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis
104. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani
105. Efficacies of KY62 against Leishmania amazonesis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis
106. Synergistic effect of interferon-γ and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis
107. Anti-leishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, thiopurinol ribonucleoside, and of formycin B, sinefungin, and the lepidine WR6026
108. Strategies for immune intervention in visceral leishmaniasis
109. Chemotherapy and the immune response in parasitic infections
110. Treatment of experimental visceral leishmaniasis in a T cell-deficient host: Response to amphotericin B and pentamidine
111. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms
112. Models of relapse of experimental visceral leishmaniasis
113. A ten years' study of kala-azar in Tharaka (Meru District, Kenya). II. Relapses
114. Is leishmaniasis ever cured?
115. Recurrent lesions in human Leishmania braziliensis infection: Reactivation or reinfection?
116. Visceral leishmaniasis (kala-azar) in solid organ transplantation: Report of five cases and review
117. Visceral leishmaniasis in immunocompromised hosts
118. Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniasis in chronically infected BALB/c mice
119. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar
120. Absence of gamma interferon and interleukin 2 during active visceral leishmaniasis
121. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy
122. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment
123. Treatment of visceral leishmaniasis: Current status
124. Is one year follow-up justified in kala-azar post-treatment?
125. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience
126. Evaluation of amphotericin B as a first-line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar
127. Amphotericin B in resistant kala-azar in Bihar
128. Daily versus alternate day regimen of amphotericin B in the treatment of kala-azar: A randomized comparison
129. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in North Bihar, India
130. Treatment of visceral leishmaniasis unresponsive to penatmidine with amphotericin B
131. Comparison of regimens of amphotericin B deoxycholate in kala-azar
132. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: A study of 938 cases
133. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: Management of those who do not respond
134. Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources
135. Clinicoepidemiological study of drug resistance in Indian kala-azar
136. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases
137. Evidence that the high incidence of treatment failure in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani
138. Randomised controlled trial of aminosidine (paromomycin) v. sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
139. Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar: A comparative study
140. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic
141. Interferon-γ in host antimicrobial defense: Current and future clinical applications
142. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome
143. Visceral leishmaniasis and HIV-1 co-infection in southern France
144. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients
145. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
146. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B
147. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
148. Prophylaxis of visceral leishmaniasis in HIV-infected patients
149. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy
150. Visceral leishmaniasis in patients infected with human immunodeficiency virus
151. Visceral leishmaniasis: Another HIV-associated opportunistic infection? Report of eight cases and review of the literature
152. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
153. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy
154. Visceral leishmaniasis (kala-azar) in transplant recipients
155. Visceral leishmaniasis in renal transplant recipients: Successful treatment with liposomal amphotericin B (AmBisome)
156. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate
157. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom
158. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis
159. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=paromomycin)-antimonial combinations, a pilot study in Bihar, India
160. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: A randomised dose-finding clinical trial
161. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone
162. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion)
163. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days
164. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex (ABLC)
165. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony
166. Amphotericin B lipid complex in the management of antimony-unresponsive Indian visceral leishmaniasis
167. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex
168. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions
169. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: A randomized dose-finding study
170. Efficacy and tolerability of liposomal amphotericin B (AmBisome) in the treatment of visceral leishmaniasis in Brazil
171. Low dose liposomal amphotericin B (AmBisome) in refractory Indian visceral leishmaniasis - A multicenter study
172. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis
173. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar
174. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis
175. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
176. Treatment of kala-azar with oral fluconazole
177. Atovaquone alone or with fluconazole as oral therapy in Indian kala-azar
178. Trial of oral miltefosine for visceral leishmaniasis
179. Oral treatment of visceral leishmaniasis with miltefosine
180. Efficacy and toxicity of miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
181. Short-course oral miltefosine treatment for visceral leishmaniasis
182. Interferon-gamma, the activated macrophage and host defense against microbial challenge
183. Visceral leishmaniasis in patients with AIDS: Report of three cases treated with pentavalent antimony and interferon-γ
184. The sensitivity of Leishmania species to aminosidine
185. Clarification of comments on trial of aminosidine in visceral leishmaniasis
186. Commentary: Some good news for treatment of visceral leishmaniasis in Bihar
187. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B
188. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis
189. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic tumours
190. Phase I study of weekly oral miltefosine (hexadecyl-phosphocholine) in cancer patients
191. Suppression of post-treatment recurrence of experimental visceral leishmaniasis in T cell-deficient mice by oral miltefosine
192. rK39: A cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis
193. Rapid accurate field diagnosis of Indian visceral leishmaniasis
194. Post-kala-azar dermal leishmaniasis
195. Post-kala-azar dermal leishmaniasis in the Sudan: Clinical features, pathology and treatment
196. Endemic kala-azar in eastern Sudan: Post-kala-azar dermal leishmaniasis
197. Immunopathology of post-kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profiles
198. Treatment of post-kala-azar dermal leishmaniasis
199. Amphotericin B is superior to sodium stibogluconate in the treatment of Indian post-kala-azar dermal leishmaniasis
200. Interleukin 12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
201. Intracellular antimicrobial activity in the absence of interferon-γ: Effect of interleukin 12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice